Snapshot from Jul 25, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / NWBio presents updated DCVax-L survival data
Business clinical trial update

NWBio presents updated DCVax-L survival data

Analysis based on 6 articles · First reported Jul 08, 2026 · Last updated Jul 08, 2026

Sentiment
40
Attention
3
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The positive updated survival data could boost investor confidence in NWBio's DCVax-L platform and support its regulatory approval prospects. However, the stock remains speculative given the company's need for additional capital and the competitive landscape in glioblastoma treatment.

Biotechnology Pharmaceuticals
Event Summary

Lakefront Biotherapeutics (NWBio) announced that its Chief Technical Officer, Dr. Marnix Bosch, presented updated survival data from the Phase III trial of DCVax-L for glioblastoma at the 2026 Annual Meeting of the British Neuro-Oncology Society. The updated analyses, using individual patient-level data from multiple randomized controlled trials, showed that the median survival advantage with DCVax-L was 3.4 to 6.3 months, substantially higher than the original estimate of 2.8 months. Sensitivity analyses confirmed the robustness of the results. The company has submitted a Marketing Authorization Application in the UK, which is under review.

Key Actions
90 Lakefront Biotherapeutics presented updated survival data
Entities Involved
priv
Lakefront Biotherapeutics
NWBio presented updated survival data for its lead product DCVax-L, showing improved efficacy estimates. This strengthens its regulatory submission in the UK and may enhance its valuation.
Importance 100.0 Sentiment 60.0
per
Marnix Bosch
Dr. Bosch, as CTO, presented the data at the BNOS meeting, playing a key role in communicating the positive results.
Importance 80.0 Sentiment 50.0
ngo
British Neuro-Oncology Society
The BNOS annual meeting served as the venue for the presentation, lending scientific credibility to the data.
Importance 30.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.